Short answer
ROCKET PHARMACEUTICALS, INC. (RCKT) filed an 8-K current report with the SEC on February 26, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q1 2025 earnings results disclosed via press release: full financials in the accompanying exhibit, not summarized in this filing section.
ROCKET PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2025 earnings results disclosed via press release: full financials in the accompanying exhibit, not summarized in this filing section
- Item 2.02 filing signals formal earnings reporting event for Rocket Pharmaceuticals (RCKT), a clinical-stage gene therapy company
- Investors should review Exhibit 99.1 for actual revenue, cash runway, and pipeline spend figures
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ROCKET PHARMACEUTICALS, INC. 8-K filings
Get the next RCKT 8-K as it lands
Follow RCKT for push alerts, or ask the research agent what this filing means.